Impact Of Rising Pneumonia Cases On The Growth Of Market Driver: Leading Transformation in the Pulmonary Or Respiratory Drug Delivery Market in 2025

What industry-specific factors are fueling the growth of the pulmonary or respiratory drug delivery market?
The escalating occurrences of pneumonia are anticipated to fuel advancement in the pulmonary or respiratory drug delivery sector. Pneumonia, characterized by inflammation of the air sacs due to lung infection, often leads to the filling of these sacs with fluid or pus. This results in symptoms like coughing, fever, and breathing difficulties. Factors contributing to these increased pneumonia rates include aging demographics, compromised immune systems, respiratory diseases, air pollution, smoking habits, and the emergence of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery offers a means of direct medication targeting to the lungs for pneumonia patients. This can include antibiotics, bronchodilators, or anti-inflammatory agents, allowing for more rapid and efficacious treatment. These treatments serve to mitigate symptoms, lessen inflammation, eradicate infections, and enhance respiratory capacity, thus facilitating recovery and forestalling complications. In correlation, the Centre for Tropical Medicine and Global Health, a UK healthcare research leader, reported in November 2023 a notable increase in pneumonia cases in Kenya, totaling 793,864 in the year 2022/2023. Therefore, this surge in pneumonia cases underscores the driving force behind the growth of the pulmonary or respiratory delivery market.

Get Your Pulmonary Or Respiratory Drug Delivery Market Report Here:
https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

What Is the projected market size and growth rate for the pulmonary or respiratory drug delivery market?
In recent times, there's been substantial growth in the market size for pulmonary or respiratory drug delivery. The market will increase from $69.83 billion in 2024 to $76.38 billion in 2025, with a compound annual growth rate (CAGR) of 9.4%. The previous growth can be credited to factors such as a higher prevalence of asthma, the adoption of more sophisticated inhalation devices, global expansion in healthcare spending, improved awareness concerning respiratory illnesses, and an increased occurrence of allergic conditions.

The market for pulmonary or respiratory drug delivery is anticipated to witness significant growth in the upcoming years, expanding to $107.85 billion in 2029 with a compound annual growth rate (CAGR) of 9.0%. This growth throughout the forecast period is credited to factors such as the rising demand for personalized medicine, increased prevalence of chronic respiratory conditions, heightened focus on telemedicine, greater investments in healthcare infrastructure, and expansion in e-commerce for pharmaceutical products. Leading trends during this projection period encompass progress in particle engineering, creation of advanced nebulizers, formulation of liposomal additives, advancements in computational fluid dynamics, and the emergence of smart inhalers.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

What new trends are reshaping the pulmonary or respiratory drug delivery market and its opportunities?
Leading players in the pulmonary or respiratory drug delivery market are prioritizing technological advancements like sophisticated drug delivery systems to improve treatment effectiveness and patient adherence. Such advanced systems aid in targeted delivery and controlled release of medicines, enhancing medication efficiency and patient health results. For example, in July 2023, Viatris Inc., an American healthcare firm producing branded and generic drugs, and Kindeva Drug Delivery L.P., an organization from the US offering drug delivery solutions, introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol earned approval from the Food and Drug Administration, a US government entity. This product is the inaugural generic form of AstraZeneca's Symbicort and a metered-dose inhaler that combines budesonide and formoterol, utilized for treating asthma and chronic obstructive pulmonary disease. It is sold in two dosages, 80 micrograms and 160 micrograms, each having 4.5 micrograms of formoterol.

What major market segments define the scope and growth of the pulmonary or respiratory drug delivery market?
The pulmonary or respiratory drug delivery market covered in this report is segmented -

1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939

Which region dominates the pulmonary or respiratory drug delivery market?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the pulmonary or respiratory drug delivery industry growth?
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

What Is Covered In The Pulmonary Or Respiratory Drug Delivery Global Market Report?

•Market Size Forecast: Examine the pulmonary or respiratory drug delivery market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the pulmonary or respiratory drug delivery market for a structured understanding.
•Key Players Overview: Analyze major players in the pulmonary or respiratory drug delivery market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the pulmonary or respiratory drug delivery market.
•Segment Contributions: Evaluate how different segments drive overall growth in the pulmonary or respiratory drug delivery market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the pulmonary or respiratory drug delivery market.
•Industry Challenges: Identify potential risks and obstacles affecting the pulmonary or respiratory drug delivery market.
•Competitive Landscape: Review strategic developments in the pulmonary or respiratory drug delivery market, including expansions, agreements, and new product launches.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.